Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $65.56

Shares of Novo Nordisk A/S (NYSE:NVO) have earned an average recommendation of “Hold” from the twenty-three ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $65.5625.

NVO has been the topic of several recent analyst reports. Wolfe Research assumed coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th.

Novo Nordisk A/S Trading Down 2.3%

Shares of NVO stock opened at $50.29 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a fifty day simple moving average of $46.09 and a two-hundred day simple moving average of $45.83. The firm has a market capitalization of $224.56 billion, a PE ratio of 11.81, a PEG ratio of 4.59 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, analysts predict that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $19,519,000. Romano Brothers AND Company boosted its position in Novo Nordisk A/S by 704.0% during the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after acquiring an additional 29,978 shares in the last quarter. Capital Investment Counsel LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $3,727,000. Marathon Capital Management grew its position in shares of Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after buying an additional 25,230 shares during the last quarter. Finally, CWA Asset Management Group LLC increased its position in shares of Novo Nordisk A/S by 131.9% during the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock worth $3,917,000 after purchasing an additional 43,793 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.